Time-kill study of the in vitro antimicrobial activity of tedizolid against methicillin-resistant Staphylococcus aureus

Tanawat Nunart, Tanitta Chatsuwan, Wanchai Treyaprasert

Abstract


To evaluate the in vitro antimicrobial activity of tedizolid against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) by time-kill curve experiments. Four bacterial strains were used in methicillin susceptibility tests, including MRSA strain H0340, H5086, H6023 and H7515, obtained from Department of Microbiology at King Chulalongkorn Memorial Hospital. The minimum inhibitory concentrations (MICs) were determined by macrodilution method. The time-kill curves were conducted with a MRSA strain (H5086 strain; MIC= 0.25 µg/ml) at tested concentrations from 0.25x to 16x MIC. Time-kill studies showed that tedizolid displayed bacteriostatic activity at all concentrations with reduction in growth of <3 log10 CFU/ml. Tedizolid demonstrated a maximum effect at concentration of 8x MIC with 1.8 log10 CFU/ml reduction from the initial inoculum at 12 h. Tedizolid exhibited good in vitro antimicrobial activity for MRSA with bacteriostatic activity.


Full Text:

25-29;PDF

References


National Antimicrobial Resistance Surveillance Center (NARST). Result of antimicrobial resistance surveillance 2012. 2012 [cited 2015 August 17]. Available from: http://narst.dmsc.moph.go.th/antibiotrend.pdf.

Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. The Journal of antimicrobial chemotherapy. 1997;40(1)(1):135-6.

Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. The Lancet. 2001;358(9277):207-8.

Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. Journal of Antimicrobial Chemotherapy. 2009;63:713–5.

Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrobial agents and chemotherapy. 2008;52(12):4442-7.

Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrobial agents and chemotherapy. 2010;54(5):2063-9.

Yum JH, Choi SH, Yong D, Chong Y, Im WB, Rhee DK, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrobial agents and chemotherapy. 2010;54(12):5381-6.

Muller M, dela P, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. . Antimicrob Agents Chemother. 2004;48(2):369-77.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 24th informational supplement. CLSI document M100-S24. Wayne. PA: CLSI; 2014.

Treyaprasert W, Schmidt S, Rand KH, Suvanakoot U, Derendorf H. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. International Journal of Antimicrobial Agents. 2007;29(3):263-70.

Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines M26-A. Wayne. PA: CLSI; 1999.

Schmidt S, Schuck E, Kumar V, Burkhardt, H D. Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents - minimum inhibitory concentration versus time-kill curves. Expert opinion Drug Discov. 2007;2(6):849-60.

Betriu C, Morales G, Rodríguez-Avial I, Culebras E, Gómez M, López-Fabal F, et al. Comparative Activities of TR-700 (Torezolid) against Staphylococcal Blood Isolates Collected in Spain. Antimicrobial agents and chemotherapy. 2010;54(5):2212–5.

Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. The Journal of the American Medical Association 2013;309(6):559-69.

Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrobial agents and chemotherapy. 2012;56(8):4403-7.

Bien P, Prokocimer P, Muñoz K, Bethune C, editors. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. Poster presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 September 12–15; Boston, MA.

Sahre M, Sabarinath S, Grant M, Seubert C, Deanda C, Prokocimer P, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. International journal of antimicrobial agents. 2012;40(1):51-4.

Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrobial agents and chemotherapy. 2012;56(5):2627-34.


Refbacks

  • There are currently no refbacks.